Full-Time

Lead SW Eng in Test

Confirmed live in the last 24 hours

Natera

Natera

1,001-5,000 employees

Biotechnology firm specializing in genetic testing

Biotechnology
Healthcare

Compensation Overview

$124.8k - $156kAnnually

Senior, Expert

Company Historically Provides H1B Sponsorship

Remote in USA

Category
QA & Testing
Quality Assurance
Required Skills
Python
Ruby
JUnit
Groovy
SQL
Java
AWS
Scala
Selenium
Linux/Unix

You match the following Natera's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • BS Degree in Computer Science or similar discipline; or equivalent work experience
  • 7+ years of experience testing both front-end and server-side functionality of complex n-tier systems
  • Extensive knowledge of quality engineering methodologies, test planning, system dependencies, and product integration phases
  • Experience working with relational databases, strong practical knowledge of SQL
  • Recent hands-on experience developing test automation code using tools and libraries, such as Selenium, TestNG, Junit and others
  • Understanding of one or more programming and scripting languages, such as Java, Scala, Python, Ruby, Groovy, or other
  • Recent hands-on experience with front-end test automation tools and libraries such as Selenium, TestNG, Junit, ScalaTest, Gatling and others
  • Strong knowledge of Linux and command line shell scripting
  • Familiar with cloud platforms such as AWS
  • Strong knowledge of QA methodologies, test planning, system dependencies, and product integration phases
  • Willingness and ability to learn new testing practices, scripting languages, and subject matter
Responsibilities
  • Perform software verification, define and execute test cases and scenarios required for software quality assurance and regulatory compliance
  • Perform system analysis, assess risk, and develop strong test strategies by analyzing product design and technical specifications, and by collaborating with product managers and developers
  • Participate in building and maintaining data-driven test automation framework using automation tools and libraries
  • Perform debugging and root cause analysis of product issues or defects
  • Evangelize new testing methodologies, best practices and tools with goals to continuously improve test coverage
  • Work closely with developers in all phases of SDLC to build quality into our development process
Desired Qualifications
  • Healthcare IT experience is beneficial, but not required
  • Experience working in regulated environments is a plus

Natera focuses on genetic testing and diagnostics, utilizing cell-free DNA (cfDNA) testing to analyze DNA fragments in the blood for cancer detection and organ health assessment. Their products include the Signatera test for cancer patients and the Panorama NIPT for prenatal screening, with a strong emphasis on personalized genetic counseling. Natera stands out by providing specialized testing services directly to healthcare providers and patients, ensuring early detection of health issues. The company's goal is to improve patient care through advanced genetic testing solutions.

Company Size

1,001-5,000

Company Stage

IPO

Total Funding

$149.9M

Headquarters

Austin, Texas

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased adoption of liquid biopsy techniques boosts demand for Natera's cfDNA tests.
  • Growing personalized medicine trend enhances need for Natera's customized genetic tests.
  • Expansion of telehealth services aligns with Natera's remote genetic counseling offerings.

What critics are saying

  • Allegations of deceptive practices could harm Natera's reputation and lead to legal issues.
  • New Prospera Heart features may face adoption challenges without independent validation.
  • Ongoing legal investigations could result in financial penalties affecting Natera's stability.

What makes Natera unique

  • Natera's Signatera test offers significant lead time in detecting cancer recurrence.
  • Prospera Heart test integrates Donor Quantity Score for enhanced transplant rejection detection.
  • Panorama NIPT uniquely determines fetal RhD status, aiding in prenatal care.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

10%
BioSpace
Feb 19th, 2025
Natera To Report Its Fourth Quarter And Full Year Results On February 27, 2025

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2024, after the market closes on Feb. 27, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m

MarketBeat
Nov 24th, 2024
Alpha DNA Investment Management LLC Invests $505,000 in Natera, Inc. (NASDAQ:NTRA)

Alpha DNA Investment Management LLC invests $505,000 in Natera, Inc. (NASDAQ:NTRA).

MarketBeat
Sep 22nd, 2024
Delap Wealth Advisory LLC Makes New $454,000 Investment in Natera, Inc. (NASDAQ:NTRA)

Delap Wealth Advisory LLC makes new $454,000 Investment in Natera, Inc. (NASDAQ:NTRA).

Investing.com
Jul 2nd, 2024
Natera CFO sells over $539k in company stock

In other recent news, Natera Inc. has launched the DECIPHER trial for gastroesophageal adenocarcinoma (EGC) treatment, utilizing its molecular residual disease (MRD) test, Signatera.

Yahoo Finance
Jun 17th, 2024
Natera Launches Differentiated New Feature For Prospera(Tm) Heart Test, Enhancing Detection Of Rejection For Transplant Patients

Donor Quantity Score (DQS) technique is unique to Natera, improving detection of both acute cellular rejection and antibody-mediated rejectionAUSTIN, Texas, June 17, 2024--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of Prospera Heart™ with Donor Quantity Score (DQS), further enhancing Prospera’s ability to detect rejection in heart transplant patients.Traditionally, donor-derived cell-free DNA (dd-cfDNA) tests have reported rejection risk based only on the fraction of dd-cfDNA in the blood vs. the total cfDNA (dd-cfDNA %). This fraction can be confounded by fluctuations in the amount of background total cfDNA (the denominator), which are sometimes caused by factors unrelated to the health of the transplant, including infection, surgery, or chemotherapy.Prospera Heart now incorporates a second metric – the DQS – that normalizes for the background total cfDNA. Prospera Heart with DQS combines the traditional donor fraction and the new DQS into a two-threshold algorithm, delivering a single result with more accurate risk assessment for both antibody mediated rejection (AMR) and acute cellular rejection (ACR)."Over the last two decades, Natera has pioneered cfDNA testing across women’s health, oncology, and transplant medicine," said Michael Olymbios, M.D., Medical Director, Heart Transplant. "Our extensive experience with cfDNA and Natera’s culture of continuous innovation drove us to further refine Prospera Heart by introducing this two-threshold algorithm to better serve the transplant community."A study performed at the University of Utah and the University of California San Diego showed that incorporating DQS enhanced the performance of Prospera Heart in screening for biopsy-proven active rejection